New CAR t therapy targets Hard-to-Treat blood cancer
NCT ID NCT07248176
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new treatment called BCMA-UCART for adults with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to see if the treatment is safe and to get an early look at how well it controls the disease. Only 6 people will take part in this study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghi Tongji Hospital (Tongji Hospital of Tongji University)
RECRUITINGShanghai, 620000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a Triple-Drug cocktail tame resistant myeloma?